Oesophageal and gastric cancer in Scotland 1960-90 - PubMed (original) (raw)
Oesophageal and gastric cancer in Scotland 1960-90
A McKinney et al. Br J Cancer. 1995 Feb.
Free PMC article
Abstract
In Scotland over the last 31 years the incidence of gastric cancer has significantly declined by 0.6% per annum in males and 1.1% in females. In contrast, for oesophageal cancer, incidence rates have risen significantly by 3.0% and 2.0% per annum in males and females respectively. Increasing incidence of both adenocarcinomas and squamous carcinomas of the oesophagus in men and squamous and recently adenocarcinomas in women has been observed. This cannot be entirely accounted for by a growth in the proportion of histologically verified (HV) tumours over time. The incidence of adenocarcinoma of the stomach increased over the study period, most likely because of increasing proportions of HV tumours and improved diagnostic precision. Areas with high levels of deprivation in Scotland are strongly associated with high rates of oesophageal cancer in men, and of gastric cancer in both men and women. All these observations are discussed in the context of current knowledge of risk factors for these diseases.
Similar articles
- Increased incidence of adenocarcinomas at the gastro-oesophageal junction in Dutch males since the 1990s.
Wijnhoven BP, Louwman MW, Tilanus HW, Coebergh JW. Wijnhoven BP, et al. Eur J Gastroenterol Hepatol. 2002 Feb;14(2):115-22. doi: 10.1097/00042737-200202000-00004. Eur J Gastroenterol Hepatol. 2002. PMID: 11981334 - Socioeconomic status and risk of adenocarcinoma of the oesophagus and cancer of the gastric cardia in Scotland.
Brewster DH, Fraser LA, McKinney PA, Black RJ. Brewster DH, et al. Br J Cancer. 2000 Aug;83(3):387-90. doi: 10.1054/bjoc.2000.1110. Br J Cancer. 2000. PMID: 10917556 Free PMC article. - Increasing prevalence of adenocarcinoma of the oesophagus and gastro-oesophageal junction: a study of the Swedish population between 1970 and 1997.
Walther C, Zilling T, Perfekt R, Möller T. Walther C, et al. Eur J Surg. 2001 Oct;167(10):748-57. doi: 10.1080/11024150152707725. Eur J Surg. 2001. PMID: 11775726 - Review article: oesophago-gastric adenocarcinoma -- an epidemiological perspective.
Forman D. Forman D. Aliment Pharmacol Ther. 2004 Oct;20 Suppl 5:55-60; discussion 61-2. doi: 10.1111/j.1365-2036.2004.02133.x. Aliment Pharmacol Ther. 2004. PMID: 15456465 Review. - The multidisciplinary management of gastrointestinal cancer. Epidemiology of oesophagogastric cancer.
Lambert R, Hainaut P. Lambert R, et al. Best Pract Res Clin Gastroenterol. 2007;21(6):921-45. doi: 10.1016/j.bpg.2007.10.001. Best Pract Res Clin Gastroenterol. 2007. PMID: 18070696 Review.
Cited by
- The pattern of recurrence of adenocarcinoma of the oesophago-gastric junction.
Wayman J, Bennett MK, Raimes SA, Griffin SM. Wayman J, et al. Br J Cancer. 2002 Apr 22;86(8):1223-9. doi: 10.1038/sj.bjc.6600252. Br J Cancer. 2002. PMID: 11953876 Free PMC article. - Effects of neutropenia and histological responses in esophageal squamous cell carcinoma with neo-adjuvant chemotherapy.
Konishi H, Fujiwara H, Shiozaki A, Hiramoto H, Kosuga T, Komatsu S, Ichikawa D, Okamoto K, Otsuji E. Konishi H, et al. Int J Clin Oncol. 2016 Feb;21(1):95-101. doi: 10.1007/s10147-015-0875-7. Epub 2015 Jul 21. Int J Clin Oncol. 2016. PMID: 26194809 - Increasing incidence of adenocarcinoma of the gastroesophageal junction and distal stomach in Canada -- an epidemiological study from 1964-2002.
Parfitt JR, Miladinovic Z, Driman DK. Parfitt JR, et al. Can J Gastroenterol. 2006 Apr;20(4):271-6. doi: 10.1155/2006/175751. Can J Gastroenterol. 2006. PMID: 16609756 Free PMC article. - A pooled analysis of dietary sugar/carbohydrate intake and esophageal and gastric cardia adenocarcinoma incidence and survival in the USA.
Li N, Petrick JL, Steck SE, Bradshaw PT, McClain KM, Niehoff NM, Engel LS, Shaheen NJ, Risch HA, Vaughan TL, Wu AH, Gammon MD. Li N, et al. Int J Epidemiol. 2017 Dec 1;46(6):1836-1846. doi: 10.1093/ije/dyx203. Int J Epidemiol. 2017. PMID: 29040685 Free PMC article. - Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.
Reid BJ, Prevo LJ, Galipeau PC, Sanchez CA, Longton G, Levine DS, Blount PL, Rabinovitch PS. Reid BJ, et al. Am J Gastroenterol. 2001 Oct;96(10):2839-48. doi: 10.1111/j.1572-0241.2001.04236.x. Am J Gastroenterol. 2001. PMID: 11693316 Free PMC article.
References
- Cancer. 1987 Sep 1;60(5):1094-8 - PubMed
- Hum Pathol. 1986 May;17(5):482-7 - PubMed
- Int J Cancer. 1988 Mar 15;41(3):331-5 - PubMed
- Cancer Res. 1988 Jul 1;48(13):3843-8 - PubMed
- Jpn J Cancer Res. 1988 Oct;79(10):1067-74 - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical